Investors

Alligator Bioscience AB is a leading biotech company developing innovative immune activating antibody drugs for tumor-directed immunotherapy. Alligator Bioscience share is listed on the Nasdaq Stockholm since November 23, 2016 and the company has presently approximately 6,800 shareholders.

For further information, please contact:
Cecilia Hofvander, Director Investor Relations & Communications
ir@alligatorbioscience.com
Tel: +46 46 540 82 00
Direct: +46 46 540 82 06